Hormonal
SGLT2 inhibitors reduce the risk of heart failure hospitalization and cardiovascular death in patients with type 2 diabetes, regardless of baseline ejection fraction or diabetes status.
If you have Type 2 Diabetes and Heart Failure (or are at high risk), ask your doctor about SGLT2 inhibitors (like Jardiance or Farxiga). These drugs are proven to significantly reduce the risk of being hospitalized for heart failure and dying from cardiovascular causes, regardless of your heart's pumping ability. They are now considered a standard part of treatment for this condition.
SGLT2i have been associated with favorable outcomes in both hard CV outcomes and quality of life... Dapagliflozin (in DAPA-HF) and Empagliflozin in EMPEROR-Reduced have been effective in reducing the risk of CV death or HF hospitalization in patients with HFrEF (by approximately 25%), regardless of T2DM status [72,73].
Why this rating
Based on multiple large-scale CVOTs (DAPA-HF, EMPEROR-Reduced, DELIVER, EMPEROR-Preserved, SOLOIST-WHF) and meta-analyses.
Source
Cardio‐renal‐metabolic disease in primary care setting
Mahmoud Ibrahim et al. · Diabetes/Metabolism Research and Reviews · 2023
DOI 10.1002/dmrr.3755
More from this paper
- GLP-1 receptor agonists (GLP1RAs) and SGLT2 inhibitors should be used as first-line treatment in patients with Type 2 Diabetes and initial kidney disease, combined with Metformin.Strong
- Intensive glycemic control (HbA1c <6.5%) in the first year after diagnosis of Type 2 Diabetes significantly reduces the 10-year risk of microvascular and macrovascular complications compared to higher HbA1c levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →